2020 ASCO, 2023 NCCN, 2023 MASCC/ESMO, and 2019 CCO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in cancer patients

Support Care Cancer. 2024 Apr 10;32(5):280. doi: 10.1007/s00520-024-08462-x.

Abstract

Chemotherapy-induced nausea and vomiting (CINV) is a common toxicity that may impair the quality of life of patients with various malignancies ranging from early to end stages. In light of frequent changes to the guidelines for optimal management of CINV, we undertook this narrative review to compare the most recent guidelines published by ASCO (2020), NCCN (2023), MASCC/ESMO (2023), and CCO (2019). The processes undertaken by each organization to evaluate existing literature were also described. Although ASCO, NCCN, MASCC/ESMO, and CCO guidelines for the treatment and prevention of CINV share many fundamental similarities, the literature surrounding low and minimal emetic risk regimens is lacking. Current data regarding adherence to these guidelines is poor and warrants further investigation to improve care.

Keywords: Antiemetic; Chemotherapy-induced nausea and vomiting; Guidelines; Prophylaxis.

Publication types

  • Review

MeSH terms

  • Antiemetics* / pharmacology
  • Antineoplastic Agents* / adverse effects
  • Humans
  • Nausea / chemically induced
  • Nausea / drug therapy
  • Nausea / prevention & control
  • Neoplasms* / drug therapy
  • Quality of Life
  • Vomiting / chemically induced
  • Vomiting / drug therapy
  • Vomiting / prevention & control

Substances

  • Antiemetics
  • Antineoplastic Agents